Baricitinib

INDICATIONS AND USAGE

LuciBaric is a Janus kinase (JAK) inhibitor indicated for:

The treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers.

Limitations of Use:

Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

The treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.

The treatment of adult patients with severe alopecia areata.

Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologi munomodulators, cyclosporine or other potent immunosuppressant

DOSAGE AND ADMINISTRATION

Administration Instructions:

See the full prescribing information for recommended evaluations and immunizations prior to treatment.

Rheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt LuciBaric in patier with  anemia (hemoglobin <8 g/dL), lymphopenia (AL <500 cells/mm’) or neutropenia (AN<1000 cells/mm’).

COVID-19: Avoid initiation or interrupt LuciBaric in patients with lymphopenia (ALC <20 ells/mm’) or neutropenia (ANC<500 cells/mm”

Recommended Dosage:

Rheumatoid Arthritis: 2umg arc daily be used as monotierpy of in combinaion with mecharesae or other non-biologic DMARDs.

COVID-19:4 mg once daily for up to 14 days.

Alopecia Areata: 2mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate.

For patients with nearly complete or complete scalp hair loss, with or without substantial yelash or eyebrow hair loss, consider treating with 4 mg once daily

Reducethe dose to 2 mg once daily when an adequate response has been achieved dosage Modifications in Patients with Renal or Hepatic Impairment,or Cytopeni:

See the full prescribing information for dosage modifications by indicatio

DOSAGE FORMS AND STRENGTHS

Tablets: 2 mgx30 tablets